Formulation, Evaluation, and Performance Optimization of Patient-Centric Orodispersible Tablets of Empagliflozin

 Background: Type 2 diabetes mellitus (T2DM) demands lifelong pharmacological management, and patient compliance is a primary factor in therapeutic success. Empagliflozin, a selective sodium-glucose cotransporter-2 (SGLT2) inhibitor, provides powerful glycemic control along with significant cardioprotective and renoprotective benefits. However, conventional oral tablets can present swallowing challenges (dysphagia) for geriatric and pediatric patient populations, potentially leading to non-adherence. Orodispersible tablets (ODTs) offer an ideal solution by disintegrating rapidly within the oral cavity without the need for water.